Turck Dominique, Bresson Jean-Louis, Burlingame Barbara, Dean Tara, Fairweather-Tait Susan, Heinonen Marina, Hirsch-Ernst Karen Ildico, Mangelsdorf Inge, McArdle Harry J, Naska Androniki, Neuhäuser-Berthold Monika, Nowicka Grażyna, Pentieva Kristina, Sanz Yolanda, Siani Alfonso, Sjödin Anders, Stern Martin, Tomé Daniel, Vinceti Marco, Willatts Peter, Engel Karl-Heinz, Marchelli Rosangela, Pöting Annette, Poulsen Morten, Schlatter Josef Rudolf, Ackerl Reinhard, van Loveren Henk
EFSA J. 2017 Nov 13;15(11):e05060. doi: 10.2903/j.efsa.2017.5060. eCollection 2017 Nov.
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to provide a supplementary dietary exposure and safety assessment of synthetic l-ergothioneine for those groups of the population which had been excluded by the applicant in the original application, i.e. infants and young children (i.e. toddlers), pregnant and breastfeeding women. Thus, intake estimates were calculated for these population groups and the following maximum anticipated daily intakes of l-ergothioneine from the NF, in addition to the background diet, were calculated: 2.82 mg/kg body weight (bw) per day for infants, 3.39 mg/kg bw per day for toddlers and 1.31 mg/kg bw per day for adults including pregnant and breastfeeding women. The Panel considers that based on the overall toxicological data the no-observed-adverse-effect level (NOAEL) of 800 mg/kg bw per day as established in the original assessment also pertains to pregnant and breastfeeding women as well as to young children (i.e. toddlers) and infants. The corresponding margins of exposure (i.e. the ratio between the NOAEL and the maximum anticipated daily intakes) are 284 for infants, 236 for young children and 610 for pregnant and breastfeeding women. These margins of exposure are considered sufficient. The Panel concludes that the novel food, synthetic l-ergothioneine, is safe under the proposed uses and use levels for infants, young children (i.e. toddlers) and pregnant and breastfeeding women.
应欧盟委员会的要求,欧洲食品安全局(EFSA)的营养产品、营养与过敏专家组(NDA)被要求针对申请人在原始申请中排除的人群,即婴儿和幼儿(即学步儿童)、孕妇和哺乳期妇女,对合成左旋麦角硫因进行补充膳食暴露和安全性评估。因此,计算了这些人群的摄入量估计值,并计算了除背景饮食外,这些人群从新型食品中预计的每日最大左旋麦角硫因摄入量:婴儿为每天2.82毫克/千克体重,学步儿童为每天3.39毫克/千克体重,包括孕妇和哺乳期妇女在内的成年人每天为1.31毫克/千克体重。专家组认为,根据总体毒理学数据,原始评估中确定的每天800毫克/千克体重的未观察到有害作用水平(NOAEL)也适用于孕妇、哺乳期妇女以及幼儿(即学步儿童)和婴儿。相应的暴露边际(即NOAEL与预计每日最大摄入量之比),婴儿为284,幼儿为236,孕妇和哺乳期妇女为610。这些暴露边际被认为是足够的。专家组得出结论,新型食品合成左旋麦角硫因在拟议的使用方式和使用水平下,对婴儿、幼儿(即学步儿童)、孕妇和哺乳期妇女是安全的。